• De Novo Purine Biosynthesis Is Essential for Magnaporthe ory

  2026-06-21

  Liu et al. (2022) demonstrate that de novo purine nucleotide biosynthesis is indispensable for fungal development and pathogenicity in Magnaporthe oryzae. By dissecting genetic and signaling components, the study reveals how disruption of this pathway impairs growth, stress response, and TOR kinase activity, illuminating new research avenues for fungal biology and crop protection.

• HMGB1 as an Early Serum Biomarker for Diabetic Nephropathy

  2026-06-20

  Peng et al. (2024) provide a robust quantitative proteomics analysis identifying HMGB1 as a promising early serum biomarker for monitoring diabetic nephropathy progression. Their integrative bioinformatics and experimental validation approach offers new precision tools for disease stratification and noninvasive detection.

• Palmitic acid (Hexadecanoic Acid): Technical Use & Protocols

  2026-06-19

  Palmitic acid (SKU N2456) provides a high-purity, well-characterized saturated long-chain fatty acid for in vitro studies targeting lipid metabolism, protein palmitoylation, and metabolic disorder models. It is not suitable for protocols requiring aqueous solubility or long-term storage of solutions. Researchers benefit from its defined purity and reproducibility in signaling and metabolic pathway investigations.

• Cyclo (-RGDfC): Protocol Optimization for Integrin αvβ3 Targ

  2026-06-19

  Cyclo (-RGDfC) empowers researchers to dissect integrin αvβ3-driven tumor biology, enabling precision in cell adhesion, migration, and targeted delivery assays. Here, we translate bench findings into actionable workflows, troubleshooting strategies, and comparative insights for maximizing research reproducibility.

• ACE2 Peptidase Activity: Substrate Specificity and Implicati

  2026-06-18

  This study systematically characterizes the substrate specificity of ACE2, highlighting its critical role in the conversion of angiotensin II to the vasodilatory Angiotensin (1-7). The findings clarify how substrate structure dictates ACE2 activity, with implications for hypertension, fibrosis, and translational research on the renin-angiotensin system.

• Applied Protocols for Tivozanib (AV-951) in Oncology Researc

  2026-06-18

  Tivozanib (AV-951) stands apart as a highly selective and potent VEGFR inhibitor, streamlining anti-angiogenic assay development and maximizing translational relevance in renal and solid tumor models. This article delivers actionable protocol enhancements, troubleshooting strategies, and comparative insights for researchers optimizing Tivozanib-driven workflows.

• Practical Use of Bradykinin (BA5201) in Vasodilator Research

  2026-06-17

  Bradykinin (BA5201) is a validated endothelium-dependent vasodilator peptide for modeling vascular permeability, smooth muscle contraction, and inflammation signaling in research contexts. It is not suitable for diagnostic or clinical use, and its solutions require prompt use due to stability constraints.

• Optimizing Cancer Assays with JNJ-26854165 (Serdemetan) SKU

  2026-06-17

  This article provides scenario-driven, rigorously referenced guidance for leveraging JNJ-26854165 (Serdemetan) (SKU A4204) in cell viability and apoptosis assays. By dissecting real-world challenges in cancer research, it demonstrates how this HDM2 inhibitor delivers reliable, quantifiable results. APExBIO’s formulation, storage, and workflow guidance are critically evaluated for bench scientists seeking reproducible outcomes.

• Palmitic acid (Hexadecanoic Acid): Technical Use and Protoco

  2026-06-16

  Palmitic acid (SKU N2456) provides a high-purity, well-characterized saturated long-chain fatty acid for in vitro research on lipid metabolism, protein palmitoylation, and metabolic disorder pathways. This product is not recommended for protocols requiring aqueous solubility or long-term solution storage, making precise handling and preparation essential for reliable results.

• Valemetostat: Dual EZH1/2 Inhibition in Adult T-cell Leukemi

  2026-06-16

  The reference study presents the first clinical approval of valemetostat, a dual inhibitor targeting EZH1 and EZH2, for relapsed or refractory adult T-cell leukemia/lymphoma (ATL). This work highlights the mechanistic rationale and clinical promise of dual epigenetic inhibition for aggressive hematological malignancies, setting a new direction for targeted cancer therapy.

• Lumiracoxib in Selective COX-2 Inhibition: Assays, Workflows

  2026-06-15

  Lumiracoxib empowers precise dissection of COX-2-mediated pathways, offering researchers unrivaled selectivity and solubility for inflammation and revascularization models. Explore workflow enhancements, troubleshooting strategies, and data-driven insights inspired by the latest vascular injury research.

• Bardoxolone Methyl: Translating Redox Mastery into Disease M

  2026-06-15

  This thought-leadership article explores Bardoxolone methyl (CDDO methyl ester) as a transformative asset for translational researchers navigating the complexities of redox modulation in disease modeling. Integrating mechanistic insights on KEAP1-Nrf2 and NF-kB pathways with recent advances in thioredoxin system biology, the article delivers actionable guidance for experimental design, competitive positioning, and future innovation—anchored by APExBIO’s industry-grade reagent.

• Gemcitabine: Mechanism, Evidence, and Applications in Cancer

  2026-06-14

  Gemcitabine (4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one) is a potent DNA synthesis inhibitor with broad applications in apoptosis and DNA damage response assays. Its mechanism and validated efficacy underpin its role in cancer research, with clear protocols and known limitations.

• Intravesical p21 mRNA-LNP Therapy: A New Approach for Bladde

  2026-06-13

  This article examines a recent study demonstrating that intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) restores tumor suppressor function and suppresses tumor growth in non–muscle-invasive bladder cancer. The findings highlight a promising, localized mRNA therapy strategy that overcomes key limitations of current treatments and provide mechanistic and preclinical support for clinical translation.

• Ziprasidone Hydrochloride (A5350): Reliable GOT1 Inhibition

  2026-06-12

  This evidence-driven article explores how Ziprasidone Hydrochloride (SKU A5350) addresses critical challenges in cell viability and proliferation assays. By dissecting real-world laboratory scenarios, it demonstrates the compound’s reproducibility, mechanistic specificity, and practical handling advantages—positioning it as a validated choice for tumor metabolism and receptor signaling research.

453 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page